Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Other Operating Expenses (2016 - 2025)

Cytosorbents (CTSO) has disclosed Other Operating Expenses for 14 consecutive years, with -$6.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses fell 19.25% year-over-year to -$6.0 million, compared with a TTM value of -$19.6 million through Sep 2025, up 9.15%, and an annual FY2024 reading of -$16.3 million, up 36.88% over the prior year.
  • Other Operating Expenses was -$6.0 million for Q3 2025 at Cytosorbents, down from -$5.8 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $1.2 million in Q2 2023 and bottomed at -$6.9 million in Q1 2024.
  • Average Other Operating Expenses over 5 years is -$1.7 million, with a median of $641205.0 recorded in 2021.
  • The sharpest move saw Other Operating Expenses skyrocketed 77.9% in 2023, then plummeted 1135.78% in 2024.
  • Year by year, Other Operating Expenses stood at $641205.0 in 2021, then grew by 18.3% to $758569.0 in 2022, then plummeted by 547.26% to -$3.4 million in 2023, then increased by 25.31% to -$2.5 million in 2024, then plummeted by 135.63% to -$6.0 million in 2025.
  • Business Quant data shows Other Operating Expenses for CTSO at -$6.0 million in Q3 2025, -$5.8 million in Q2 2025, and -$5.2 million in Q1 2025.